Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

BACKGROUND. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ∼4 mont...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ray-Coquard, Isabelle, Italiano, Antoine, Bompas, Emmanuelle, Le Cesne, Axel, Robin, Yves-Marie, Chevreau, Christine, Bay, Jacques-Olivier, Bousquet, Guilhem, Piperno-Neumann, Sophie, Isambert, Nicolas, Lemaitre, Laurent, Fournier, Charles, Gauthier, Eric, Collard, Olivier, Cupissol, Didier, Clisant, Stéphanie, Blay, Jean-Yves, Penel, Nicolas
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2012
Matèries:
Sarcomas
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286175/
https://ncbi.nlm.nih.gov/pubmed/22285963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0237
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars